@article{11435b324d904e328ea0122633b10966,
title = "Gender issues from the perspective of health-care professionals in Neuro-oncology: An EANO and EORTC Brain Tumor Group survey",
abstract = "Background: Women represent an increasing proportion of the overall workforce in medicine but are underrepresented in leadership roles. Methods: To explore gender inequalities and challenges in career opportunities, a web-based survey was conducted among the membership of the European Association of Neuro-Oncology and the Brain Tumor Group of the European Organisation for Research and Treatment of Cancer. Results: A total of 228 colleagues responded to the survey: 129 women (median age 45 years; range, 25-66 years) and 99 men (median age 48 years; range, 24-81 years); 153 participants (67%) were married and 157 participants (69%) had at least 1 child. Women less often declared being married (60% vs 77%, P =. 007) or having a child (63% vs 77%, P =. 024). Men more frequently had a full-time position (88% vs 75%, P =. 036). Women and men both perceived an underrepresentation of women in leadership positions. Half of participants agreed that the most important challenges for women are leading a team and obtaining a faculty position. Fewer women than men would accept such a position (42% vs 56%). The main reasons were limited time for career and an inappropriate work and life balance. Women specifically cited negative discrimination, limited opportunities, and lack of self-confidence. Discrimination of women at work was perceived by 64% of women vs 47% of men (P =. 003). Conclusion: Women are perceived as experiencing more difficulties in acquiring a leadership position. Personal preferences may account for an underrepresentation of women in leadership positions, but perceived gender inequalities extend beyond disparities of access to leadership.",
keywords = "disparities, equality, leadership, oncology, women",
author = "{Le Rhun}, Emilie and Michael Weller and Niclou, {Simone P.} and Susan Short and Karin Piil and Florien Boele and Roberta Rud{\`a} and Marilena Theodorou and Dieta Brandsma and {Van Den Bent}, Martin and Linda Dirven",
note = "Funding Information: Conflict of interest statements. ELR has received research grants from Mundipharma and Amgen and honoraria for lectures or advisory board participation from Abbvie, Daiichy Sankyo, Mundipharma, and Novartis. RR has received honoraria for lectures or advisory board participation from UCB, Novocure, and Eisai. MW has received research grants from Abbvie, Adastra, Bristol-Meyers Squibb (BMS), Dracen, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, Piqur, and Roche, and honoraria for lectures or advisory board participation or consulting from Abbvie, Basilea, BMS, Celgene, MSD, Merck (EMD), Novocure, Orbus, Roche, and Tocagen. LD, SPN, SS, KP, FB, MT, DB, and MvdB have nothing to declare. Funding Information: The authors thank Magdalena Mara and Anja Rosenkranz and the entire European Association of Neuro-Oncology team as well as the European Organisation for Research and Treatment of Cancer Brain Tumor Group headquarter team for their support. The authors thank all participants for time and effort to work on the questionnaire. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Publisher Copyright: {\textcopyright} 2020 The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.",
year = "2020",
month = mar,
day = "19",
doi = "10.1093/nop/npz053",
language = "English",
volume = "7",
pages = "249--259",
journal = "Neuro-Oncology Practice",
issn = "2054-2577",
publisher = "Oxford University Press",
number = "2",
}